跳至主要内容
临床试验/NCT00456976
NCT00456976已完成早期 1 期

Efficacy of Selegiline Augmentation of Antipsychotic Medication to Treat Negative Symptoms in Inpatients With Chronic Schizophrenia

Tabriz University2 个研究点 分布在 2 个国家目标入组 70 人开始时间: 2007年4月1日最近更新:
适应症
相关药物

试验速览

阶段
早期 1 期
状态
已完成
发起方
入组人数
70
试验地点
2
主要终点
decreasing in negative symptoms in case group

研究概览

简要总结

Antipsychotic drugs are effective in treating the positive symptoms of schizophrenia; however their efficacy in treating negative symptoms is limited. This study wants to evaluate efficacy of selegiline augmentation of antipsychotic medication to treat negative symptoms in inpatients with chronic schizophrenia. With randomized clinical trial two groups of patients will select to receive selegiline or placebo.

Primary end point is decreasing in negative symptoms in case group. Inclusion criteria : 1- Patients with moderate to severe negative symptoms 2- Patients with at least one year antipsychotic drug therapy, at the current dose >= 1 month. 3- No other psychotropic drugs during past month. Exclusion criteria: 1- Severe major depressive disorder, substance abuse, severe positive symptoms of schizophrenia, Treatment of MDD with antidepressant drugs during past month.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
20 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with moderate to severe negative symptoms
  • Patients with at least one year antipsychotic drug therapy, at the current dose >= 1 month.
  • No other psychotropic drugs during past month

排除标准

  • Severe major depressive disorder
  • Substance abuse
  • Severe positive symptoms of schizophrenia
  • Treatment of MDD with antidepressant drugs during past month.

结局指标

主要结局

decreasing in negative symptoms in case group

次要结局

未报告次要终点

研究者

发起方
Tabriz University
申办方类型
Other

研究点 (2)

Loading locations...

相似试验